Abeona Therapeutics Inc. (ABEO)
NASDAQ: ABEO · IEX Real-Time Price · USD
3.260
+0.070 (2.19%)
At close: Apr 26, 2024, 4:00 PM
3.310
+0.050 (1.53%)
After-hours: Apr 26, 2024, 7:57 PM EDT
Abeona Therapeutics Revenue
In the year 2023, Abeona Therapeutics had annual revenue of $3.50M with 147.52% growth.
Revenue (ttm)
$3.50M
Revenue Growth
+147.52%
P/S Ratio
25.48
Revenue / Employee
$41,667
Employees
84
Market Cap
89.18M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 3.50M | 2.09M | 147.52% |
Dec 31, 2022 | 1.41M | -1.59M | -52.87% |
Dec 31, 2021 | 3.00M | -7.00M | -70.00% |
Dec 31, 2020 | 10.00M | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 3.00M | 2.16M | 258.18% |
Dec 31, 2017 | 837.00K | -52.00K | -5.85% |
Dec 31, 2016 | 889.00K | -151.00K | -14.52% |
Dec 31, 2015 | 1.04M | 115.00K | 12.43% |
Dec 31, 2014 | 925.00K | -1.12M | -54.70% |
Dec 31, 2013 | 2.04M | -2.36M | -53.63% |
Dec 31, 2012 | 4.40M | 2.54M | 135.63% |
Dec 31, 2011 | 1.87M | 1.34M | 251.98% |
Dec 31, 2010 | 531.00K | 179.00K | 50.85% |
Dec 31, 2009 | 352.00K | 61.00K | 20.96% |
Dec 31, 2008 | 291.00K | 234.00K | 410.53% |
Dec 31, 2007 | 57.00K | - | - |
Dec 31, 2006 | 0 | - | - |
Dec 31, 2005 | 0 | - | - |
Dec 31, 2004 | 0 | - | - |
Dec 31, 2003 | 0 | - | - |
Dec 31, 2002 | 1.15M | 904.00K | 372.02% |
Dec 31, 2001 | 243.00K | 136.00K | 127.10% |
Dec 31, 2000 | 107.00K | 92.00K | 613.33% |
Dec 31, 1999 | 15.00K | - | - |
Dec 31, 1998 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
PetMed Express | 276.97M |
Assertio Holdings | 152.07M |
Protalix BioTherapeutics | 65.49M |
Allurion Technologies | 53.47M |
Gritstone bio | 16.34M |
Curis | 10.02M |
Atara Biotherapeutics | 8.57M |
ABEO News
- 4 days ago - US FDA declines to approve Abeona's skin disorder treatment - Reuters
- 4 days ago - Abeona Therapeutics Provides Regulatory Update on Pz-cel - GlobeNewsWire
- 26 days ago - Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections - GlobeNewsWire
- 3 months ago - Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA) - GlobeNewsWire
- 3 months ago - Abeona Therapeutics Announces $50 Million Credit Facility - GlobeNewsWire
- 5 months ago - Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA) - GlobeNewsWire
- 5 months ago - Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments - GlobeNewsWire